NCT07159620View on ClinicalTrials.gov

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2030

Conditions

Adult T-cell Leukemia/Lymphoma

Interventions

DRUG

VEN (Venetoclax)

Orally

DRUG

Azacitidine (AZA)

Subcutaneous injection

DRUG

Chidamide

Orally

DRUG

vindesine

intravenous infusion

DRUG

Dexamethasone

intravenous infusion or orally

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT07159620 - Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients | Biotech Hunter | Biotech Hunter